CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3802-3811

  Overdevest, Jonathan B ^a   Thomas, Shibu ^a   Kristiansen, Glen ^b   Hansel, Donna E ^c   Smith, Steven C ^a   Theodorescu, Dan ^d,e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD24; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD24; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 79957899607     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0519     Document Type: Article

References (48)

1. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy dtudy on 367 patients. Urol Int 1999;62:69-75. (Pubitemid 29401703)
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
3. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
4. Vale C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34. (Pubitemid 36694580)
5. Pirruccello SJ, LeBien TW. The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986;136: 3779-84. (Pubitemid 16122078)
6. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66:1917-22.
7. Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009;15:5518-27.
8. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008;68:2803-12. (Pubitemid 351556279)
9. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-95. (Pubitemid 27229826)
10. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12:1241-51. (Pubitemid 28418954)
11. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone H-J, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60:6714-22.
12. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005;65:10783-93. (Pubitemid 41715227)
13. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A 2009;106:5807-12.
14. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucl Acids Res 1990;18:3587-96.
15. Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2006;26:765-73. (Pubitemid 46204255)
16. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000;27: 252-63. (Pubitemid 30067454)
17. Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, et al. Endothelin axis is a target of the lung metastasis suppressor gene3 RhoGDI2. Cancer Res 2005;65:7320-7. (Pubitemid 41161264)
18. Nitz MD, Harding MA, Theodorescu D, William E, Balch CJD, Alan H, et al. Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol 2008;439:219-33.
19. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, Chirgwin J, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7. (Pubitemid 41161264)
20. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89. (Pubitemid 46622045)
21. Kristiansen G, Machado E, Bretz N, Rupp C, Winzer KJ, K€onig AK, et al. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest 2010;90: 1102-16.
22. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23. (Pubitemid 35364098)
23. Durandy A, Brousse N, Rozenberg F, De Saint Basile G, Fischer A, Fischer A. Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies. J Clin Invest 1992;30:945-52.
24. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, et al. Anti-B-cell monoclonal antibodies in the treatment of severe Bcell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-6.
25. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and longterm outcome. Blood 1998;92:3137-47. (Pubitemid 28492320)
26. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67: 1030-7.
28. Fidler I. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-20-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
29. Rasch E. DNA "standards" and the range of accurate DNA estimates by Feulgen absorption microspectrophotometry. Prog Clin Biol Res 1985;196:137-66.
30. Tiersch TR, Chandler RW, Wachtel SS, Elias S. Reference standards for flow cytometry and application in comparative studies of nuclear DNA content. Cytometry 1989;10:706-10.
31. Hardie DC, Gregory TR, Hebert PD. From pixels to picograms: a beginners' guide to genome quantification by Feulgen image analysis densitometry. J Histochem Cytochem 2002;50:735-50.
32. Weber E, Lehmann HP, Beck-Sickinger AG, Wawrzynczak EJ, Waibel R, Folkers G, et al. Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucinealanine- proline. Clin Exp Immunol 1993;93:279-85. (Pubitemid 23238041)
33. Lee J-H, Kim S-H, Lee E-S, Kim Y-S. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009;22: 1149-56.
34. Kristiansen G, Pilarsky C, Pervan J, St€urzebecher B, Stephan C, Jung K, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183-92. (Pubitemid 38160906)
35. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain- Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73. (Pubitemid 46349843)
36. Kim YS, Gum J Jr, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996;13:693-707. (Pubitemid 26354262)
37. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42. (Pubitemid 40942829)
38. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006;7:599-604. (Pubitemid 43827326)
39. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255-62. (Pubitemid 40585311)
40. L€aubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010;20:169-77.
41. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve nonmucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A 2002;99:2193-8. (Pubitemid 34169037)
42. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161: 1215-21.
43. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574-81. (Pubitemid 41338997)
44. Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol 2005;97:379-86. (Pubitemid 40614878)
45. Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2006;202:569-76. (Pubitemid 44057770)
46. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007;14:2748-58.
47. Choi YL, Lee SH, Kwon GY, Park CK, Han JJ, Choi JS, et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med 2007;131:275-81.
48. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou A-M, Tsipis A, Patsouris E. CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 2009;205:524-33.